The leading global voice
We play a major role in bringing the CV community together to drive transformational change.
Together we are stronger
By 2025, our aim is to reduce premature deaths from CVD by at least 25%.
Join the fight
Become a WHF member and help us to build global commitment to address cardiovascular health at the policy level.
We convene and connect our members
To share science, best practice and resources, acting as a global thought leader and catalyst for positive change.
Celebrate World Heart Day
The biggest global awareness-raising campaign for CVD.
Attend the Congress
Join world leaders in heart health, share ideas, network with specialists.
Advocating for heart health
We lead the global advocacy effort for action to prevent, control and reduce the global burden of CVD.
All our programmes and partnerships are aimed at creating awareness of CVD as a priority issue across the globe.
Find out more about our and our members’ work around the world.
Explore everything from toolkits, videos and infographics, to policy reports, factsheets and more.
Find out more about our and our members' work around the world.
A symposium on “Fixed-dose combinations for cardiovascular disease and hypertension: Perspectives and lessons learned from HIV/AIDS and TB” will be held at the London School of Hygiene and Tropical Medicine on July 3rd from 9am to 5pm.
The Global Centre for Chronic Conditions at LSHTM, the George Institute for Global Health, Sydney and Médecins sans Frontières will co-host this symposium.
Fixed-dose combinations (FDC) for prevention of atherosclerotic cardiovascular disease (CVD), including FDCs for secondary prevention and hypertension, have shown promising results but progress on their uptake and use has been slow. Notably, applications to include these FDCs for secondary prevention and hypertension in the World Health Organization (WHO) Essential Medicine List (EML) have not been successful.
This international symposium will bring experts working on FDCs for CVD and hypertension together with experts working in the fields of HIV and TB, as well as representatives from governmental, non-governmental organizations, industry and funders. The final aim is to provoke a lively discussion around the barriers to FDC implementation, particularly in relation to the EML and to explore the next steps in moving this agenda forward through further research, advocacy and policy change.
Professor Baron Peter Piot, Director of the London School of Hygiene & Tropical Medicine, will give the welcome address and speakers will include Dr Helen Bygrave, MSF Access Campaign, Dr Ruth Webster, The George Institute for Global Health, Dr Stephen MacMahon, Professor of Global Health, University of Oxford, and Dr Giorgio Roscigno, Global Alliance for TB Drug Development and representatives from the World Health Organization, among others.
WHF launches Report on Hypertension Roadmap implementation in Kenya
Happy New Year 2019 with a look back on 2018
Global Alliance for Chronic Diseases publishes Hypertension Programme Report